Nothing Special   »   [go: up one dir, main page]

SI2086332T1 - Iz kostnega mozga pridobljene mezenhimske matične celice kot vir nevralnih predhodnikov - Google Patents

Iz kostnega mozga pridobljene mezenhimske matične celice kot vir nevralnih predhodnikov Download PDF

Info

Publication number
SI2086332T1
SI2086332T1 SI200732020T SI200732020T SI2086332T1 SI 2086332 T1 SI2086332 T1 SI 2086332T1 SI 200732020 T SI200732020 T SI 200732020T SI 200732020 T SI200732020 T SI 200732020T SI 2086332 T1 SI2086332 T1 SI 2086332T1
Authority
SI
Slovenia
Prior art keywords
stem cells
mesenchymal stem
neural
bone marrow
neural precursors
Prior art date
Application number
SI200732020T
Other languages
English (en)
Inventor
Saud A. Sadiq
Violane K. HARRIS
Original Assignee
Multiple Sclerosis Research Center Of New York
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Multiple Sclerosis Research Center Of New York filed Critical Multiple Sclerosis Research Center Of New York
Publication of SI2086332T1 publication Critical patent/SI2086332T1/sl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0618—Cells of the nervous system
    • C12N5/0622—Glial cells, e.g. astrocytes, oligodendrocytes; Schwann cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/30—Nerves; Brain; Eyes; Corneal cells; Cerebrospinal fluid; Neuronal stem cells; Neuronal precursor cells; Glial cells; Oligodendrocytes; Schwann cells; Astroglia; Astrocytes; Choroid plexus; Spinal cord tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0618—Cells of the nervous system
    • C12N5/0619—Neurons
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0618—Cells of the nervous system
    • C12N5/0623—Stem cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0663—Bone marrow mesenchymal stem cells (BM-MSC)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/11—Epidermal growth factor [EGF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/115—Basic fibroblast growth factor (bFGF, FGF-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/13—Nerve growth factor [NGF]; Brain-derived neurotrophic factor [BDNF]; Cilliary neurotrophic factor [CNTF]; Glial-derived neurotrophic factor [GDNF]; Neurotrophins [NT]; Neuregulins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/08—Coculture with; Conditioned medium produced by cells of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/13—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells
    • C12N2506/1346—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells from mesenchymal stem cells
    • C12N2506/1353—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells from mesenchymal stem cells from bone marrow mesenchymal stem cells (BM-MSC)

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Claims (9)

  1. Iz kostnega mozga pridobljene mezenhimske matične celice kot vir nevralnih predhodnikov Patentni zahtevki
    1. Postopek za in vitro diferenciacijo nevralnih prekurzorskih celic iz mezenhimskih matičnih celic, pridobljenih iz kostnega mozga, pri čemer postopek obsega: (a) ekspandiranje izoliranih iz kostnega mozga pridobljenih mezenhimskih matičnih celic, pobranih od pacienta, v bazalnem mediju, ki obsega avtologni rastni serum, pridobljen od pacienta; (b) gojenje in izoliranje iz mezenhimskih matičnih celic pridobljenih nevralnih prekurzorskih celic od mezenhimskih matičnih celic; in (c) izvajanje analize izražanja genov za identificiranje iz mezenhimskih matičnih celic pridobljenih nevralnih predhodnikov, ki kažejo 2-4-kratno povečanje količine nestina, 5-15-kratno povečanje količine nevrofilamenta, 7-10-kratno povečanje količine GFAF (glialna fibrilarna kisla beljakovina) in 0,4-0,7-kratno zmanjšanje vimentina.
  2. 2. Postopek po zahtevku 1, pri čemer korak (b) obsega gojenje mezenhimskih matičnih celic, pridobljenih iz koraka (a) v bazalnem mediju nevralnih prednikov (NPBM), obogatenem z nevronskim preživetvenim faktorjem-1 (NSF-1), 20 ng/ml epidermalnega rastnega faktorja (EGF) in 20 ng/ml bazičnega fibroblastnega rastnega faktorja (bFGF), da nastanejo nevralni predniki.
  3. 3. Postopek po zahtevku 2, pri čemer je EGF rekombinantni človeški EGF (rhEGF) in bFGF je rekombinantni človeški bFGF (rhbFGF).
  4. 4. Postopek po katerem koli predhodnem zahtevku, pri čemer se mezenhimske matične celice v koraku (a) in nevralni prekurzorji v koraku (b) gojijo na gojitvenih bučkah 2 majhnim sprijemanjem.
  5. 5. Postopek po katerem koli od zahtevkov od 2 do 4, pri čemer se nevralni prekurzorji izolirajo tako, da se poberejo plavajoče celične gruče nevralnih prekurzorjev, prednostno s centrifugiranjem, in se pobrane celice resuspendirajo v oplemenitenem gojitvenem mediju NPBM.
  6. 6. Postopek po zahtevku 5, pri čemer se pobiranje plavajočih celičnih gruč nevralnih prekurzorjev in resuspendiranje v oplemenitenem gojitvenem mediju NPBM opravi vsakih 2-3 dni.
  7. 7. Postopek po katerem koli predhodnem zahtevku, pri čemer se iz matičnih celic pridobljeni nevralni prekurzorji gojijo v koraku (b) 10-15 dni.
  8. 8. Postopek po katerem koli predhodnem zahtevku, pri čemer analiza izražanja genov obsega analiziranje RNA-ravni nestina, nevrofilamenta, glialne fibrilarne kisle beljakovine (GFAP) in vimentina v vzorcu nevronskih prekurzorskih celic in vzorcu mezenhimskih matičnih celic.
  9. 9. Postopek po katerem koli predhodnem zahtevku, pri čemer ima posameznik multiplo sklerozo.
SI200732020T 2006-11-03 2007-11-02 Iz kostnega mozga pridobljene mezenhimske matične celice kot vir nevralnih predhodnikov SI2086332T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US85651506P 2006-11-03 2006-11-03
PCT/US2007/023184 WO2008057443A2 (en) 2006-11-03 2007-11-02 Bone marrow-derived mesenchymal stem cells as a source of neural progenitors
EP07867349.8A EP2086332B1 (en) 2006-11-03 2007-11-02 Bone marrow-derived mesenchymal stem cells as a source of neural progenitors

Publications (1)

Publication Number Publication Date
SI2086332T1 true SI2086332T1 (sl) 2018-06-29

Family

ID=39365076

Family Applications (1)

Application Number Title Priority Date Filing Date
SI200732020T SI2086332T1 (sl) 2006-11-03 2007-11-02 Iz kostnega mozga pridobljene mezenhimske matične celice kot vir nevralnih predhodnikov

Country Status (15)

Country Link
US (5) US8642331B2 (sl)
EP (2) EP3031326A3 (sl)
CA (1) CA2668200C (sl)
CY (1) CY1120115T1 (sl)
DK (1) DK2086332T3 (sl)
ES (1) ES2663875T3 (sl)
HR (1) HRP20180533T1 (sl)
HU (1) HUE036745T2 (sl)
LT (1) LT2086332T (sl)
MX (1) MX2009004776A (sl)
PL (1) PL2086332T3 (sl)
PT (1) PT2086332T (sl)
RS (1) RS57083B1 (sl)
SI (1) SI2086332T1 (sl)
WO (1) WO2008057443A2 (sl)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT2086332T (lt) 2006-11-03 2018-04-25 Multiple Sclerosis Research Center Of New York Mezenchiminės kamieninės ląstelės, gautos iš kaulų čiulpų, kaip neuroninių pradininkų šaltinis
US9301975B2 (en) 2009-05-01 2016-04-05 Biocardia, Inc. Method of preparing autologous cells and method of use for therapy
US20120020931A1 (en) 2010-06-02 2012-01-26 Rutgers, The State University Of New Jersey Therapeutic encapsulated embryonic stem cells and mesenchymal stromal cells
EP2605765B1 (en) 2010-08-18 2019-05-08 Theresa Deisher Dexamethasone for use in treating osteoarthritis, liver failure, type-2 diabetes mellitus, stroke and parkinson's disease, in combination with stem cell treatment
EP2624845A4 (en) * 2010-10-08 2015-09-09 Mesoblast Internat S Rl REINFORCED MSC PREPARATIONS
WO2012070964A1 (ru) * 2010-11-22 2012-05-31 Farber Boris Slavinovich Модифицированные олигопептиды с противораковыми свойствами и способ их получения
EP3058063B1 (en) 2013-10-14 2018-06-06 Hadasit Medical Research Services and Development Ltd. Method of obtaining terminally differentiated neuronal lineages
WO2015143074A1 (en) * 2014-03-20 2015-09-24 University Of Southern California Brain cancer immunotherapy
WO2016168993A1 (en) 2015-04-22 2016-10-27 Innolife Co., Ltd. Methods of tissue repair and regeneration
JP2018517743A (ja) 2015-06-15 2018-07-05 メイヨ・ファウンデーション・フォー・メディカル・エデュケーション・アンド・リサーチ 多系統萎縮症を治療するための自家間葉系幹細胞の使用
CN108291207A (zh) 2015-10-08 2018-07-17 神经元治疗公司 神经前体细胞群体及其用途
CA3062123A1 (en) 2017-05-15 2018-11-22 Stem Cell Medicine Ltd. Treatment of multiple sclerosis with adipose-derived stem cells
WO2018211486A1 (en) 2017-05-15 2018-11-22 Stem Cell Medicine Ltd. Treatment of multiple sclerosis with long acting glatiramer and adipose-derived stem cells
WO2021020666A1 (en) * 2019-07-26 2021-02-04 Brexogen Inc. Precursor cells of induced pluripotent stem cell-derived mesenchymal stem cells and method for preparing the same

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7037719B1 (en) 1999-02-12 2006-05-02 Stemcells California, Inc. Enriched central nervous system stem cell and progenitor cell populations, and methods for identifying, isolating and enriching for such populations
US8017112B2 (en) * 1999-05-14 2011-09-13 Henry Ford Health System Transplantation of bone marrow stromal cells for treatment of neurodegenerative diseases
US20040208858A1 (en) * 2000-04-12 2004-10-21 Gihan Tennekoon Therapeutic uses for mesenchymal stromal cells
CA2465653C (en) * 2001-10-30 2013-10-08 Renomedix Institute Inc. Method for inducing differentiation of mesodermal stem cells, es cells, or immortalized mesodermal stem cells into neural cells
CN101243178A (zh) * 2005-06-16 2008-08-13 特拉维夫大学拉莫特有限公司 用于治疗cns疾病的分离细胞和包含这种细胞的细胞群
LT2086332T (lt) 2006-11-03 2018-04-25 Multiple Sclerosis Research Center Of New York Mezenchiminės kamieninės ląstelės, gautos iš kaulų čiulpų, kaip neuroninių pradininkų šaltinis

Also Published As

Publication number Publication date
CA2668200C (en) 2017-04-18
HUE036745T2 (hu) 2018-07-30
US20150118198A1 (en) 2015-04-30
HRP20180533T1 (hr) 2018-05-18
CA2668200A1 (en) 2008-05-15
WO2008057443A9 (en) 2008-07-17
DK2086332T3 (en) 2018-04-16
EP2086332A4 (en) 2010-08-11
US20100166712A1 (en) 2010-07-01
EP3031326A2 (en) 2016-06-15
RS57083B1 (sr) 2018-06-29
US20140308745A1 (en) 2014-10-16
EP2086332A2 (en) 2009-08-12
MX2009004776A (es) 2009-07-14
WO2008057443A3 (en) 2008-11-20
EP2086332B1 (en) 2018-01-10
CY1120115T1 (el) 2018-12-12
PT2086332T (pt) 2018-04-04
US9657268B2 (en) 2017-05-23
US20110236357A1 (en) 2011-09-29
US8642331B2 (en) 2014-02-04
WO2008057443A2 (en) 2008-05-15
LT2086332T (lt) 2018-04-25
PL2086332T3 (pl) 2018-07-31
EP3031326A3 (en) 2016-09-14
ES2663875T3 (es) 2018-04-17
US20150064145A1 (en) 2015-03-05
US9328329B2 (en) 2016-05-03

Similar Documents

Publication Publication Date Title
SI2086332T1 (sl) Iz kostnega mozga pridobljene mezenhimske matične celice kot vir nevralnih predhodnikov
CN103031275A (zh) 脐带间充质干细胞分化为神经干细胞的诱导方法
CN106893692A (zh) 用于单细胞分选与增强ipsc重新编程的细胞培养平台
CN112048470B (zh) 一种利用人诱导多能干细胞制备临床级别间充质干细胞制剂的方法
CN113151149A (zh) 一种经济简便诱导肺类器官的方法及实验模型的建立
CN104774808B (zh) 将脐带间充质干细胞诱导分化成γ-氨基丁酸能神经元的方法
Dai et al. The Human Skin‐Derived Precursors for Regenerative Medicine: Current State, Challenges, and Perspectives
KR20190060716A (ko) 무혈청 배지 조성물
CN108998410A (zh) 蛋白激酶抑制剂在抑制单倍体细胞二倍化中的用途
CN104789531B (zh) 一种将脐带间充质干细胞诱导分化成多巴胺能神经元的方法
CN118048296B (zh) 一种用于细胞重编程的培养体系、试剂盒及方法
KR101760239B1 (ko) 세포배양 삽입체를 이용한 인간 배아줄기세포 유래 중간엽 세포의 분리방법
CN112852709A (zh) 小鼠肺类器官培养方法
Goorha et al. Culturing and neuronal differentiation of human dental pulp stem cells
CN107164325B (zh) MSCs来源的少突胶质细胞的制备方法及试剂盒
KR101204894B1 (ko) 줄기세포의 외배엽성 세포로의 분화 방법
Yasuda et al. Development of cystic embryoid bodies with visceral yolk-sac-like structures from mouse embryonic stem cells using low-adherence 96-well plate
CN100475956C (zh) 制备用于移植的细胞的方法
JPWO2006028049A1 (ja) アストロサイト様細胞馴化培地の製造方法
CN106085951A (zh) 一种建立可持续传代的树鼩精原干细胞细胞系的方法
US20230113241A1 (en) Automated method for preparing keratinocytes
CN111235110A (zh) 一种神经干细胞的体外培养方法
US20230119089A1 (en) Method for differentiating pluripotent stem cells into underlying connective tissue fibroblasts of an epithelium
EP1775340A1 (en) Method of cell transdifferentiation
US8796014B2 (en) Method for producing tissue cells from pluripotent stem cells derived from iris pigment epithelial cells of animal and tissue cell obtained by method